Q-omics provides the consensus-scored NDUFA5P11 profile across patient tissues and cancer cell-line models. NDUFA5P11 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NDUFA5P11 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, NDUFA5P11 RNA expression shows 15,608 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where NDUFA5P11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NDUFA5P11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NDUFA5P11 survival associations across molecular data types. NDUFA5P11 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NDUFA5P11 RNA expression–survival associations across cancer types. High NDUFA5P11 expression shows unfavorable associations in KICH and DLBC, but favorable associations in KIRC, MESO, READ and OV. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for NDUFA5P11 RNA expression.
This table summarizes NDUFA5P11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for NDUFA5P11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NDUFA5P11 shows lower tumor expression in THCA, KIRC and KIRP and higher tumor expression in COAD, BRCA and LUAD. The THCA box plot shows higher NDUFA5P11 RNA expression in normal versus tumor tissue (log2 FC = −0.575, t-test p < 0.001).
This table shows molecular features associated with NDUFA5P11 in patient tissues and cancer cell lines. In patient samples, NDUFA5P11 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
